CA-PATIENT-SAFETY
8.9.2020 14:07:09 CEST | Business Wire | Press release
Today, the Patient Safety Movement Foundation released a detailed white paper and its leadership issued the following statement urging the creation of a National Patient Safety Board:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005576/en/
“COVID-19 has exposed the safety gaps in our healthcare system that already cause 200,000 deaths a year. We need a National Patient Safety Board.
The U.S. death toll from COVID-19 is also approaching 200,000, with The New York Times recently reporting that the milestone may already have been crossed when considering that ‘official death counts may be substantially underestimating the overall effects of the virus.’ But even pre-pandemic, more than 200,000 Americans die each year from another epidemic: preventable errors in hospitals. This fact makes preventable medical harm the unspoken third-leading cause of death in the U.S. If you’re shocked, you’re not alone: 79 percent of Americans don’t know that the safety of patients is compromised every day in healthcare.
Health worker safety is patient safety, and we’re at a breaking point in this cause as the death tolls intersect.
The reality is systemic problems in healthcare, such as a failure to embrace a transparent and just culture or the failure to implement known solutions to challenges like healthcare-associated infections and medication safety, have been continuously setting up our health workers for failure and error year after year. Negative OSHA rates, DART rates and the medical profession generally topping the career-burnout lists meant the crisis was always starting on a shaky foundation. Now with COVID-19 pushing health workers to the breaking point, the issue couldn’t be more timely. 2020 has been one of the most challenging and eye-opening years for the issues of safety in our healthcare systems, from effectively equipping and supporting frontline health workers in their important work to equitably serving and treating patients. More than 1,000 caregivers have lost their lives doing what they love doing best – taking care of patients. According to NBC News and a survey conducted by nursing app Holliblu, 62 percent of more than 1,000 respondents said they are planning to quit either their jobs or the profession altogether because of the pandemic. This is unacceptable.
We need a National Patient Safety Board.
Despite the fanfare around medical technology and breakthroughs, the fastest and most sustainable solutions for saving more than 200,000 lives per year -- and more, during pandemics and other extraordinary challenges -- is reducing the number of system and process breakdowns. We must put health workers, and thus patients, first by finally establishing a National Patient Safety Board (NPSB). This would solve the problem in three key ways:
- Data-driven insight and standards: An NPSB would create and maintain a National Patient Safety Database to receive non-identifiable patient safety work product. The Board would facilitate the reporting, collection, and analysis of patient safety data and the development and dissemination of training guidelines and other recommendations to reduce medical errors and improve patient safety and quality of care.
- Transparency and accountability: The NPSB would also require an on-going analysis of the patient safety data in the Database and other available data to determine performance and systems standards, tools, and best practices (including peer review) for doctors and other health care providers necessary to prevent medical errors, improve patient safety, and increase accountability within the health care system.
- Align incentives: An NPSB would save lives and taxpayer dollars by aligning incentives, especially Medicare reimbursements, with proven patient safety protocols.
COVID-19 shouldn’t be the breaking point for our health workers, but it should be the breaking point for our tolerance of the lack of patient safety. Congress must act today on this bipartisan issue.”
About the Patient Safety Movement Foundation
Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers, and private payers together under the same cause. From our Actionable Patient Safety Solutions and industry Open Data Pledge to our World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until we achieve zero.
For more information, please visit www.patientsafetymovement.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005576/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
